Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...

Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue expectations , with sales up 16% year on year to $811.1 million. The company’s ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Exact Sciences’ (NDAQ: EXAS) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, “Exact,” as the company is known, went public in 2001 but struggled to find its footing, ...

Exact Sciences is an oncology diagnostics company that has a strong position in stool-based DNA testing for colorectal cancer. The cancer diagnostics market is large, and growing, but blood-based ...

Exact Sciences has moved to acquire Genomic Health, with plans to bring their cancer screening and diagnostic tests up through a combined commercial organization of about 1,000 employees, including ...